Advertisement
11/23/2021

Amneal receives FDA nod for generic Durezol

Durezol and its generics had a market value of roughly $103 million in the 12 months ended September 2021, according to IQVIA.
Sandra Levy
Senior Editor
Sandra Levy profile picture
diagram

The Food and Drug Administration has given Amneal its blessing for difluprednate ophthalmic emulsion 0.05%.

The product is the generic of Durezol.

[Read more: Amneal intros generic Trisenox]

It is used in the treatment of inflammation and pain associated with ocular surgery.

“With the approval of difluprednate, a complex ophthalmic suspension product, we continue to shift our portfolio to increasingly complex and more differentiated product areas. The wheel of innovation constantly turns at Amneal, and we see a long runway for our R&D engine,” said Chirag and Chintu Patel, co-CEOs.

[Read more: Amneal launches 1st generic of Intelence]

Durezol and its generics had a market value of roughly $103 million in the 12 months ended September 2021, according to IQVIA.

Advertisement
Advertisement